Combination of Electroconvulsive Therapy and Clozapine in Treatment-Resistant Schizophrenia. 2018

Jung Hyun Kim, and Tak Youn, and Jun Gwon Choi, and Seong Hoon Jeong, and Hee Yeon Jung, and Yong Sik Kim, and In Won Chung
Department of Psychiatry & Electroconvulsive Therapy Center, Dongguk University International Hospital, Goyang, Republic of Korea.

OBJECTIVE This study aimed to investigate the effectiveness and tolerability of the combination of electroconvulsive therapy (ECT) in patients with clozapine-treated schizophrenia. METHODS Patients with clozapine-treated schizophrenia during five years of pre-determined period were recruited from Electronic Medical Record. Clinical effects of acute ECT on psychotic symptoms were investigated. We also tried to identify predictive variables requiring maintenance treatment of ECT. RESULTS Fourteen patients received ECT and clozapine and sixteen were treated with clozapine alone. In the ECT group, which could be refined as clozapine-resistance, PANSS total score was significantly reduced by 19.0±9.9 points, corresponding to a reduction rate of 18.5±8.3%. The clinical remission defined as 20% PANSS reduction criteria was achieved at 42.9%. The subscale factors were significantly reduced, among which the negative symptom was the least. There was no difference in demographic and clinical information between patients receiving and not receiving maintenance ECT, and not all patients seemed to need maintenance ECT if clozapine is continued. CONCLUSIONS Combination of ECT and clozapine in patients with clozapine-resistant schizophrenia resulted in a rapid and substantial reduction of psychotic symptoms. Further studies are needed to improve the effectiveness and tolerability of ECT.

UI MeSH Term Description Entries

Related Publications

Jung Hyun Kim, and Tak Youn, and Jun Gwon Choi, and Seong Hoon Jeong, and Hee Yeon Jung, and Yong Sik Kim, and In Won Chung
April 1999, Progress in neuro-psychopharmacology & biological psychiatry,
Jung Hyun Kim, and Tak Youn, and Jun Gwon Choi, and Seong Hoon Jeong, and Hee Yeon Jung, and Yong Sik Kim, and In Won Chung
April 2023, Biomedicines,
Jung Hyun Kim, and Tak Youn, and Jun Gwon Choi, and Seong Hoon Jeong, and Hee Yeon Jung, and Yong Sik Kim, and In Won Chung
January 2006, Clinical neuropharmacology,
Jung Hyun Kim, and Tak Youn, and Jun Gwon Choi, and Seong Hoon Jeong, and Hee Yeon Jung, and Yong Sik Kim, and In Won Chung
December 2011, The journal of ECT,
Jung Hyun Kim, and Tak Youn, and Jun Gwon Choi, and Seong Hoon Jeong, and Hee Yeon Jung, and Yong Sik Kim, and In Won Chung
August 2001, The Australian and New Zealand journal of psychiatry,
Jung Hyun Kim, and Tak Youn, and Jun Gwon Choi, and Seong Hoon Jeong, and Hee Yeon Jung, and Yong Sik Kim, and In Won Chung
October 2016, Medwave,
Jung Hyun Kim, and Tak Youn, and Jun Gwon Choi, and Seong Hoon Jeong, and Hee Yeon Jung, and Yong Sik Kim, and In Won Chung
December 2009, The journal of ECT,
Jung Hyun Kim, and Tak Youn, and Jun Gwon Choi, and Seong Hoon Jeong, and Hee Yeon Jung, and Yong Sik Kim, and In Won Chung
January 2019, International medical case reports journal,
Jung Hyun Kim, and Tak Youn, and Jun Gwon Choi, and Seong Hoon Jeong, and Hee Yeon Jung, and Yong Sik Kim, and In Won Chung
June 2004, Human psychopharmacology,
Jung Hyun Kim, and Tak Youn, and Jun Gwon Choi, and Seong Hoon Jeong, and Hee Yeon Jung, and Yong Sik Kim, and In Won Chung
January 2019, Focus (American Psychiatric Publishing),
Copied contents to your clipboard!